Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$330.52M$330.52M−46.0% vs Q1 2025 Net Income$330.96M$330.96MN/M vs Q1 2025 EPS Diluted$2.88$2.88N/M vs Q1 2025 Operating Income$358,433,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Free Cash Flowderived-$204,764,000N/M Margins · derivedOperating margin108.4%+157.6 pt vs Q1 2025
Net margin100.1%+173.3 pt vs Q1 2025
ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end